New York State Teachers Retirement System Raises Stock Position in Glaukos Co. (NYSE:GKOS)

New York State Teachers Retirement System grew its stake in Glaukos Co. (NYSE:GKOS) by 0.2% during the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 48,243 shares of the medical instruments supplier’s stock after acquiring an additional 100 shares during the period. New York State Teachers Retirement System owned about 0.09% of Glaukos worth $7,234,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also made changes to their positions in GKOS. Asset Planning Inc acquired a new position in shares of Glaukos in the fourth quarter valued at approximately $90,000. Legato Capital Management LLC grew its holdings in shares of Glaukos by 85.0% in the fourth quarter. Legato Capital Management LLC now owns 9,381 shares of the medical instruments supplier’s stock valued at $1,407,000 after purchasing an additional 4,309 shares in the last quarter. Louisiana State Employees Retirement System grew its holdings in shares of Glaukos by 0.4% in the fourth quarter. Louisiana State Employees Retirement System now owns 26,700 shares of the medical instruments supplier’s stock valued at $4,003,000 after purchasing an additional 100 shares in the last quarter. Empowered Funds LLC acquired a new position in shares of Glaukos in the fourth quarter valued at approximately $236,000. Finally, KBC Group NV grew its holdings in shares of Glaukos by 67.3% in the fourth quarter. KBC Group NV now owns 2,417 shares of the medical instruments supplier’s stock valued at $362,000 after purchasing an additional 972 shares in the last quarter. 99.04% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In other Glaukos news, insider Tomas Navratil sold 3,416 shares of Glaukos stock in a transaction on Friday, February 14th. The shares were sold at an average price of $147.14, for a total value of $502,630.24. Following the completion of the transaction, the insider now owns 72,437 shares of the company’s stock, valued at $10,658,380.18. The trade was a 4.50 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, Director Gilbert H. Kliman sold 10,000 shares of Glaukos stock in a transaction on Friday, December 20th. The stock was sold at an average price of $150.28, for a total transaction of $1,502,800.00. Following the completion of the transaction, the director now directly owns 32,336 shares of the company’s stock, valued at approximately $4,859,454.08. This represents a 23.62 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 18,744 shares of company stock worth $2,792,151 over the last 90 days. Company insiders own 6.40% of the company’s stock.

Glaukos Trading Up 5.5 %

NYSE GKOS opened at $161.30 on Thursday. Glaukos Co. has a one year low of $83.90 and a one year high of $163.71. The company’s 50 day moving average price is $152.65 and its 200 day moving average price is $139.03. The company has a debt-to-equity ratio of 0.19, a quick ratio of 4.71 and a current ratio of 5.54. The firm has a market capitalization of $8.89 billion, a price-to-earnings ratio of -53.41 and a beta of 1.04.

Analyst Ratings Changes

GKOS has been the subject of a number of research reports. Truist Financial lifted their price objective on shares of Glaukos from $152.00 to $185.00 and gave the company a “buy” rating in a report on Wednesday, December 18th. Citigroup upgraded shares of Glaukos from a “neutral” rating to a “buy” rating and upped their target price for the company from $132.00 to $162.00 in a report on Wednesday, December 11th. Stephens upgraded shares of Glaukos to a “strong-buy” rating in a report on Monday, December 2nd. Mizuho upgraded shares of Glaukos from a “neutral” rating to an “outperform” rating and upped their target price for the company from $140.00 to $200.00 in a report on Wednesday. Finally, UBS Group assumed coverage on shares of Glaukos in a research report on Friday, December 6th. They issued a “buy” rating and a $182.00 price target for the company. One research analyst has rated the stock with a sell rating, one has given a hold rating, eleven have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, Glaukos currently has a consensus rating of “Moderate Buy” and a consensus price target of $159.42.

About Glaukos

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.